Advertisement

Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia

      Abstract

      Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL) associated enzyme with three activities which are paraoxonase, arylesterase and dyazoxonase. We aimed to determine serum (a) paraoxonase and arylesterase activities and, lipid hydroperoxide (LOOH) levels in patients with iron deficiency anemia (IDA) (b) whether there is an association between the development of atherosclerosis and paraoxonase/arylesterase activities in patients with IDA. Twenty-five female with IDA and 22 healthy female as control were enrolled in the study. Serum basal/salt-stimulated paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by ferrous oxidation with xylenol orange assay. Basal/salt-stimulated paraoxonase and arylesterase activities were significantly lower in patients with IDA than controls (p < 0.001; for all), while LOOH levels were significantly higher (p < 0.001). Our results show that paraoxonase and arylesterase activities, which have antiatherogenic capability, are decreased in patients with IDA. Reduced paraoxonase and arylesterase activities may play a role in pathogenesis of atherosclerosis through increased susceptibility to lipid peroxidation in patients with IDA.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • DeMaeyer E.
        • Adiels Tegman M.
        The prevalence of anaemia in the world.
        World Health Stat Q. 1985; 38: 302-316
        • Rockey D.C.
        • Cello J.P.
        Evaluation of the gastrointestinal tract in patients with iron deficiency anemia.
        N Engl J Med. 1993; 329: 1691-1695
        • Lieberman E.
        • Ryan K.J.
        • Monson R.R.
        • Schoenbaum S.C.
        Association of maternal hematocrit with premature labor.
        Am J Obstet Gynecol. 1988; 159: 107-114
        • Oski F.A.
        • Honig A.S.
        • Helu B.
        • Howanitz P.
        Effect of iron therapy on behavior performance in nonanemic, iron-deficient infants.
        Pediatrics. 1983; 71: 877-880
        • Mackness B.
        • Durrington P.N.
        • Mackness M.I.
        Human Serum. Paraoxonase.
        Gen Pharmacol. 2004; 39: 59-66
        • Canales A.
        • Sanchez-Muniz F.J.
        Paraoxanase, something more than an enzyme?.
        Med Clin (Barc). 2003; 121: 537-548
        • Blatter M.C.
        • James R.W.
        • Messmer S.
        • Barja F.
        • Pometta D.
        Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase.
        Eur J Biochem. 1993; 211: 871-879
        • Kosaka T.
        • Yamaguchi M.
        • Motomura T.
        • Mizuno K.
        Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay.
        Clin Chim Acta. 2005; 359: 156-162
        • Mackness M.I.
        • Durrington P.N.
        HDL, its enzymes and its potential to influence lipid peroxidation.
        Atherosclerosis. 1995; 115: 243-253
        • Marenberg M.E.
        • Risch N.
        • Berkman L.F.
        • Floderus B.
        • de Faire U.
        Genetic susceptibility to death from coronary heart disease in a study of twins.
        New Engl J Med. 1994; 330: 1041-1046
        • Ayub A.
        • Mackness M.I.
        • Arrol S.
        • et al.
        Serum paraoxonase after myocardial infarction.
        Arterioscler Thromb Vasc Biol. 1999; 19: 330-335
        • Mackness M.I.
        • Harty D.
        • Bhatnagar D.
        • et al.
        Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus.
        Atherosclerosis. 1991; 86: 193-199
        • Paragh G.
        • Seres I.
        • Balogh Z.
        • et al.
        The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia.
        Nephron. 1998; 80: 166-170
        • Mackness M.I.
        • Abbott C.
        • Arrol S.
        • Durrington P.N.
        The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation.
        Biochem J. 1993; 294: 829-834
        • Parthasarathy S.
        • Barnett J.
        • Fong L.G.
        High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein.
        Biochim Biophys Acta. 1990; 1044: 275-283
        • Witztum J.L.
        The oxidation hypothesis of atherosclerosis.
        Lancet. 1994; 344: 793-795
        • Watson A.D.
        • Berliner J.A.
        • Hama S.Y.
        • et al.
        Protective effect of high density lipoprotein associated paraoxonase: inhibitition of the biological activity of minimally oxidized low density lipoprotein.
        J Clin Invest. 1995; 96: 2882-2891
        • La Du B.N.
        • Piko J.I.
        • Eckerson H.W.
        • Vincent-Viry M.
        • Siest G.
        An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism.
        Ann Biol Clin. 1986; 44: 369-372
        • Brophy V.H.
        • Jampsa R.L.
        • Clendenning J.B.
        • Mckinstry L.A.
        • Furlong C.E.
        Effects of 5 V regulatory-region polymorphisms on paraoxonase-gene (PON1) expression.
        Am J Hum Genet. 2001; 68: 1428-1436
        • Suehiro T.
        • Nakamura T.
        • Inoue M.
        • et al.
        A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression.
        Atherosclerosis. 2000; 150: 295-298
        • Adkins S.
        • Gan K.N.
        • Mody M.
        • La Du B.N.
        Molecular basis for the polymorphic forms of human serum paraoxonase: arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.
        Am J Hum Genet. 1993; 52: 598-608
        • Mackness M.I.
        • Arrol S.
        • Mackness B.
        • Durrington P.N.
        The allo enzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low-density lipoprotein against lipid-peroxidation.
        Lancet. 1997; 349: 851-852
        • Mackness B.
        • Mackness M.I.
        • Arrol S.
        • Turkie W.
        • Durrington P.N.
        Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon.
        Br J Pharmacol. 1997; 112: 265-268
        • Aviram M.
        Does paraoxonase play role in susceptibility of cardiovascular disease?.
        Mol Med Today. 1999; 5: 381-386
        • Eckerson H.W.
        • Wyte M.C.
        • La Du B.N.
        The human serum paraoxonase/arylesterase polymorphism.
        Am J Hum Genet. 1983; 35: 1126-1138
        • Haagen L.
        • Brock A.
        A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate.
        Eur J Clin Chem Clim Biochem. 1992; 30: 391-395
        • Nourooz Zadeh J.
        Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma.
        Methods Enzymol. 1999; 300: 58-62
        • Halliwell B.
        Antioxidants in human health and disease.
        Annu Rev Nutr. 1996; 16: 33-50
        • Ramachandran M.
        • Iyer G.Y.
        Erythrocyte membrane lipid peroxidation in iron deficiency anemia.
        Experientia. 1984; 40: 173-174
        • Jansson L.T.
        • Perkkio M.V.
        • Willis W.T.
        • Refino C.J.
        • Dallman P.R.
        Red cell superoxide dismutase is increased in iron deficiency anemia.
        Acta Haematol. 1985; 74: 218-221
        • Macdougall L.G.
        Red cell metabolism in iron deficiency anemia. The relationship between glutathione peroxidase, catalase, serum vitamin E, and susceptibility of irondeficient red cells to oxidative hemolysis.
        J Pediatr. 1972; 80: 775-782
        • Kurtoglu E.
        • Ugur A.
        • Baltaci A.K.
        • Undar L.
        Effect of iron supplementation on oxidative stress and antioxidant status in iron deficiency anemia.
        Biol Trace Elem Res. 2003; 96: 117-123
        • Isler M.
        • Delibas N.
        • Guclu M.
        • et al.
        Superoxide dismutase and glutathione peroxidase in erythrocytes of patients with iron deficiency anemia: effects of different treatment modalities.
        Croat Med J. 2002; 43: 16-19
        • McCord J.M.
        The evolution of free radicals and oxidative stress.
        Am J Med. 2000; 108: 652-659
        • Akins P.T.
        • Glenn S.
        • Nemeth P.M.
        • Derdeyn C.P.
        Carotid artery thrombus associated with severe iron deficiency anemia and thrombocytosis.
        Stroke. 1996; 27: 1002-1005
        • Aoki N.
        • Sakai T.
        Cerebral sinus thrombosis in patients with severe iron deficiency anemia due to myoma ueri.
        Acta Neurochir (Wien). 1989; 97: 131-134
        • Shimamoto T.
        The ‘emergency reaction’ in thrombogenesis and atherogenesis.
        Am Heart J. 1963; 66: 572-573
        • Hartfield D.S.
        • Lowry N.J.
        • Keene D.L.
        • Yager J.Y.
        Iron deficiency: a cause of stroke in ınfants and children.
        Pediatr Neurol. 1997; 16: 50-53
        • Witzum J.L.
        • Steinberg D.
        Role of oxidized low density lipoprotein in atherogenesis.
        J Clin Invest. 1991; 88: 1785-1792
        • Esterbauer H.
        • Wag G.
        • Puhl H.
        Lipid peroxidation and its role in atherosclerosis.
        Br Med Bull. 1993; 49: 566-576
        • Mackness B.
        • Hunt R.
        • Durrington P.N.
        • Mackness M.I.
        Increased immunolocalization of paraoxonase, clusterin and apolipoproteins A-I in the progression of atherosclerosis.
        Arterioscler Thromb Vasc Biol. 1997; 17: 1233-1238
        • Seres I.
        • Paragh G.
        • Deschene E.
        • Fulop Jr., T.
        • Khalil A.
        Study of factors influencing the decreased HDL associated PON1 activity with aging.
        Exp Gerontol. 2004; 39: 59-66
        • Hedrick C.C.
        • Hassan K.
        • Hough G.P.
        • et al.
        Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism.
        Arterioscler Thromb Vasc Biol. 2000; 2: 1946-1952
        • James R.W.
        • Leview I.
        • Righetti A.
        Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease.
        Circulation. 2000; 101: 2252-2257
        • Shih D.M.
        • Gu L.
        • Xia Y.R.
        • et al.
        Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis.
        Nature. 1998; 394: 284-287
        • Shih D.M.
        • Xia Y.R.
        • Miller E.
        • et al.
        Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis.
        J Biol Chem. 2000; 275: 17527-17535
        • Mackness M.I.
        • Arrol S.
        • Durrington P.N.
        Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.
        FEBS Lett. 1991; 286: 152-154
        • Aviram M.
        • Rosenblat M.
        • Bisgaier C.L.
        • et al.
        Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
        J Clin Invest. 1998; 101: 1581-1590
        • Miller N.E.
        • La Ville A.
        • Crook D.
        Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit.
        Nature. 1985; 314: 109-111
        • Suehiro T.
        • Nakauchi Y.
        • Yamamoto M.
        • et al.
        Paraoxonase gene polymorphism in Japanese subjects with coronary artery disease.
        Int J Cardiol. 1996; 57: 69-73
        • Ruiz J.
        • Blanche H.
        • James R.W.
        • et al.
        Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes.
        Lancet. 1995; 346: 869-872
        • Jarvik G.P.
        • Hatsukami T.S.
        • Carlson C.
        • et al.
        Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease.
        Arterioscler Thromb Vasc Biol. 2003; 23: 1465-1471
        • Mackness B.
        • Davies G.K.
        • Turkie W.
        • et al.
        Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?.
        Arterioscler Thromb Vasc Biol. 2001; 21: 1451-1457